Injury

LyondellBasell demonstrates progress toward industry leadership in 2023 sustainability report

Retrieved on: 
Tuesday, April 9, 2024

HOUSTON and ROTTERDAM, Netherlands, April 9, 2024 /PRNewswire/ -- LyondellBasell (NYSE: LYB) today published its annual sustainability report titled, Everyday Sustainability.

Key Points: 
  • HOUSTON and ROTTERDAM, Netherlands, April 9, 2024 /PRNewswire/ -- LyondellBasell (NYSE: LYB) today published its annual sustainability report titled, Everyday Sustainability.
  • As we progress toward establishing ourselves as an industry leader in sustainability, we have moved from unlocking possibilities to making everyday sustainability a reality," said Peter Vanacker, CEO of LyondellBasell.
  • "We are committed to disclosing our sustainability performance, providing transparency and demonstrating how we support everyday sustainability," said Vanacker.
  • For more information, read the 2023 LyondellBasell sustainability report, Everyday Sustainability here .

Combatting Texting and Driving in Nashville: Dolinsky Law Group Shares Safety Tips and Legal Consequences

Retrieved on: 
Tuesday, April 9, 2024

NASHVILLE, Tenn., April 9, 2024 /PRNewswire-PRWeb/ -- In response to the persistent issue of texting and driving, Dolinsky Law Group emphasizes the critical importance of road safety through the provision of essential safety tips and clarification of the legal consequences associated with distracted driving. This effort is part of the firm's ongoing commitment to promoting safer driving practices and preventing accidents linked to the use of mobile phones behind the wheel.

Key Points: 
  • Dolinsky Law Group emphasizes road safety by providing essential tips and outlining legal consequences to combat texting and driving in Nashville.
  • NASHVILLE, Tenn., April 9, 2024 /PRNewswire-PRWeb/ -- In response to the persistent issue of texting and driving, Dolinsky Law Group emphasizes the critical importance of road safety through the provision of essential safety tips and clarification of the legal consequences associated with distracted driving.
  • For those affected by distracted driving incidents, Dolinsky Law Group offers comprehensive legal support, from navigating insurance claims to pursuing compensation for injuries and losses.
  • For more information on avoiding texting and driving or to seek legal assistance, please contact Dolinsky Law Group at (800) 474-4089 or visit https://www.duejustice.com .

Global Elbow Replacement Market to surpass $200.4 million by 2031, at a CAGR of 4.2%, says Coherent Market Insights

Retrieved on: 
Monday, April 8, 2024

Elbow replacement surgery is a medical procedure that involves replacing a damaged or diseased elbow joint with an artificial implant.

Key Points: 
  • Elbow replacement surgery is a medical procedure that involves replacing a damaged or diseased elbow joint with an artificial implant.
  • As per the market research report, the elbow replacement market was valued at USD 144.2 million in 2023, with a projected CAGR of 4.2% during the forecast period 2024-2031.
  • Buy this Complete Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/6663
    In terms of type, the elbow replacement market is segmented into partial elbow replacement and total elbow replacement.
  • Partial elbow replacement is expected to dominate the market, owing to its less invasive nature and shorter recovery time compared to total elbow replacement.

Global Elbow Replacement Market to surpass $200.4 million by 2031, at a CAGR of 4.2%, says Coherent Market Insights

Retrieved on: 
Monday, April 8, 2024

Elbow replacement surgery is a medical procedure that involves replacing a damaged or diseased elbow joint with an artificial implant.

Key Points: 
  • Elbow replacement surgery is a medical procedure that involves replacing a damaged or diseased elbow joint with an artificial implant.
  • As per the market research report, the elbow replacement market was valued at USD 144.2 million in 2023, with a projected CAGR of 4.2% during the forecast period 2024-2031.
  • Buy this Complete Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/6663
    In terms of type, the elbow replacement market is segmented into partial elbow replacement and total elbow replacement.
  • Partial elbow replacement is expected to dominate the market, owing to its less invasive nature and shorter recovery time compared to total elbow replacement.

From Reagan to Obama, presidents have left office with ‘strategic regret’ − will leaving troops in Iraq and Syria be Biden or Trump’s?

Retrieved on: 
Tuesday, April 9, 2024

U.S. presidents often leave the White House expressing “strategic regret” over perceived foreign policy failures.

Key Points: 
  • U.S. presidents often leave the White House expressing “strategic regret” over perceived foreign policy failures.
  • Lyndon Johnson was haunted by the Vietnam War.
  • Bill Clinton regretted the failed intervention in Somalia and how the “Black Hawk Down” incident contributed to his administration’s inaction over the Rwandan genocide.
  • Barack Obama said the Libyan intervention was “the worst mistake” of his presidency.

Another Beirut?

  • The Middle East has entered a volatile period.
  • The threat to U.S. personnel in the region takes the form of both the Islamic State group, which is intent on hitting Western targets, and the increased risk from a network of Iran-linked militants seeking to avenge what they see as U.S. complicity in Israel’s siege of Gaza.
  • If any mass-casualty attack on U.S. forces were to occur, the occupant of the White House would face two conditions that have left departing presidents experiencing strategic regret: the loss of American lives on their watch and the prospect of being drawn into a widening war.
  • Today’s situation in Iraq and Syria is eerily similar in many ways to the circumstances Reagan faced in Beirut, but potentially far more dangerous.
  • Like Lebanon then, U.S. troops are in Iraq and Syria for secondary, as opposed to primary, security objectives.
  • According to a recent Pentagon report, that threat remains exceedingly weak today for the United States.
  • While Reagan was unaware of the high exposure of U.S. Marines in 1983, the danger U.S. troops face today in Iraq and Syria is abundantly clear.
  • The Jordan attack aside, U.S. service members have already suffered significant injuries from missiles, including dozens of traumatic brain injuries.

Fueling hubris


Some might consider this concern about “another Beirut” overblown. After all, proxy attacks on U.S. forces in Iraq and Syria have dropped since the attack in Jordan in late January, giving the impression that deterrence is now working after big U.S. retaliatory strikes in February.

  • The 1983 Marine Corps barracks bombing was preceded a few months earlier by a smaller, yet still deadly, bombing at the U.S. embassy in Beirut.
  • In the lull that followed the embassy attack, Reagan officials didn’t pursue a strategically smart rethink of U.S. policy or consider troop reductions.
  • In short, lulls in violence like today in Iraq and Syria can fuel hubris and provide a dangerous sense of false security and a determination to stay the course.
  • As research shows, “see, I told you so” is a powerful rhetorical tool in circumstances like this.

The ghosts of history

  • But anything too large risks inviting the kind of response that could lead to lasting and devastating outcomes.
  • Imagine, for example, a scenario in which a U.S. president is provoked into striking Iran following repeated attacks by Tehran’s proxies on U.S. troops.
  • The result would be an expansion of – and further U.S. involvement in – the Middle East conflict.
  • Their experiences and the ghosts of history serve as a warning when it comes to U.S. forces in Syria and Iraq now.


Charles Walldorf received funding from Charles Koch Foundation.

Charles Walldorf is a Visiting Fellow, Defense Priorities

Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update

Retrieved on: 
Friday, March 22, 2024

DURHAM, N.C., March 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced financial results for the fourth quarter and year ended December 31, 2023 and highlighted recent corporate accomplishments in advancing the investigational Human Acellular Vessel (HAV) closer to planned U.S. market launch.

Key Points: 
  • There was no revenue for either the fourth quarter of 2023 or the fourth quarter of 2022, and there was no revenue for the year ended December 31, 2023.
  • Research and development expenses were $20.2 million for the fourth quarter of 2023, compared to $15.0 million for the fourth quarter of 2022, and were $76.6 million for the year ended December 31, 2023, compared to $63.3 million for the year ended December 31, 2022.
  • General and administrative expenses were $6.0 million for the fourth quarter of 2023, compared to $5.8 million for the fourth quarter of 2022, and were $23.5 million for the year ended December 31, 2023, compared to $22.9 million for the year ended December 31, 2022.
  • The 2023 increases in net loss resulted from the non-cash remeasurement of the contingent earnout liability, and operating expense increases, described above.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 22, 2024

The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.

Key Points: 
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • However, in response, Cassava denied the allegations in the Citizen Petition and instead touted the effectiveness of simufilam and the efficacy of the Company's research programs.
  • On this news, Cassava's stock price fell $2.68 per share, or 15.28%, to close at $14.86 per share on October 13, 2023.
  • For more information on the InMode class action go to: https://bespc.com/cases/INMD

MADD Canada Supports Administrative Sanctions at .05% -.08% BAC in Quebec

Retrieved on: 
Thursday, March 21, 2024

OAKVILLE, Ontario, March 21, 2024 (GLOBE NEWSWIRE) -- MADD Canada believes strong administrative sanctions in the .05% to .08% blood alcohol concentration (BAC) range are important to reduce impaired driving deaths and injuries.

Key Points: 
  • OAKVILLE, Ontario, March 21, 2024 (GLOBE NEWSWIRE) -- MADD Canada believes strong administrative sanctions in the .05% to .08% blood alcohol concentration (BAC) range are important to reduce impaired driving deaths and injuries.
  • All provinces in Canada, except Quebec, have administrative licence suspensions at the .05% to .08% BAC level, which has enhanced road safety.
  • MADD Canada’s National President, Tanya Hansen Pratt, knows all too well the real cost of impaired driving.
  • Surveys have shown that the majority of Quebecers support sanctions at the .05% BAC level to reduce impaired driving and related crashes and injuries.

Penn Highlands Healthcare Doctors Beyond the Borders

Retrieved on: 
Wednesday, March 20, 2024

Penn Highlands Healthcare offers 849 physicians who provide a wide range of care and treatments at locations throughout 26 counties in Pennsylvania.

Key Points: 
  • Penn Highlands Healthcare offers 849 physicians who provide a wide range of care and treatments at locations throughout 26 counties in Pennsylvania.
  • Penn Highlands Healthcare physicians can be found in the health system’s eight hospitals as well as many community medical buildings, outpatient facilities, surgery centers and physician practices.
  • Some Penn Highlands Healthcare physicians do not allow county, state or continental borders to keep them from providing care where it is needed.
  • Dr. Sergent, who is an emergency medicine physician and the Central Region Medical Director of Emergency Medicine at Penn Highlands Healthcare, shares his skills and expertise beyond the U.S. borders in Central and South America.

RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury

Retrieved on: 
Wednesday, March 20, 2024

Restoration of bladder function is ranked as one of the highest priorities by individuals with SCI (Bourbeau et al., Spinal Cord 58:1216–1226; 2020).

Key Points: 
  • Restoration of bladder function is ranked as one of the highest priorities by individuals with SCI (Bourbeau et al., Spinal Cord 58:1216–1226; 2020).
  • Current treatment approaches usually require interventions such as catheterization for urinary voiding, which have their own set of risks and potentially significant set of complications.
  • The present paper, entitled “Acute ampakines increase voiding function and coordination in a rat model of SCI” (Rana, Alom et al.
  • We believe that this research has the potential to represent a novel, breakthrough in the treatment of SCI, which is badly needed.”